Navigation Links
Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors
Date:2/3/2011

ng the international investment bank, J.P. Morgan & Co. Incorporated.  He joined Geron in 1995 as the company's Chief Financial Officer, Treasurer and Secretary and has also served as the company's Vice President of Corporate Development.  Mr. Greenwood is a director of two of the company's subsidiaries, Geron Bio-Med Limited and TA Therapeutic Ltd. as well as a director of ViaGen, Inc., an Arizona corporation, and Clone International, an Australian company.  Mr. Greenwood serves on the Board of Regents of Pacific Lutheran University from which he holds a Bachelor of Arts.  He also has an M.B.A. from Harvard Business School.

Dr. Chaudhuri and Mr. Greenwood join current Corium board members Ron Eastman, Chairman of the Board of Corium and Managing Director at Essex Woodlands Health Ventures, Dr. Phyllis Gardner, Partner at Essex Woodlands and Professor of Medicine at Stanford University, John Kozarich, Chairman and President, ActivX Biosciences, Inc., Robert Thomas, former CEO of FoxHollow Technologies, Daniel G. Welch, CEO and President of InterMune, Peter D. Staple, CEO and President of Corium and Gary W. Cleary, co-founder of Corium.  The Company is currently developing and manufacturing a pipeline of advanced transdermal products employing its proprietary MicroCor® microneedle technology and Corplex™ polymer adhesive technology.  Essex Woodlands Health Ventures has been the lead investor in Corium since 2007.

Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand Rapids, MI.

About Corium International, Inc.

Corium International, Inc. develops and manufactures products based on its advanced transdermal drug delivery technologies.  The company has developed and clinically validated two highly differentiated state of the art transdermal technologies: MicroCor® is designed for needle-free delivery of large molecules such as proteins and peptides, and Corplex
'/>"/>

SOURCE Corium International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
2. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
3. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
4. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
5. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
6. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
7. Encorium Reports Second Quarter 2010 Financial Results
8. Encorium Group, Inc. Announces Terms of Proposed Rights Offering
9. Encorium Group, Inc. Provides Update on Its Previously Announced Rights Offering
10. Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... , Aug. 20, 2014 ApolloDx™ today ... diagnostic platform during a special event at the company,s ... , on September 5, 2014. The event, which will ... the ApolloDx website, www.apollodx.com .    ... testing," said Jared Bauer , Co-Founder and Managing ...
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... England , August 20, 2014 ... be Conducted in the US  KalVista Pharmaceuticals ... macular edema (DME), today announces that it has begun ... novel plasma kallikrein inhibitor, KVD001, for the treatment of ... Sun of the Beetham Eye Institute, Joslin Diabetes Center; ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Sept. 18 A long-term study found,that a ... with life-threatening,diseases, such as leukemia and lymphoma, results ... males are likely to recover,from these changes over ... In addition, neither male nor female long-term cancer,survivors ...
... Bacterial Infection and May ... Bacterial Infections, BOSTON, Sept. 18 Paratek ... of the Company,s,Multiple Adaptation Response (MAR) inhibitor program. ... controlling virulence and antibiotic,resistance. Paratek has shown that ...
Cached Medicine Technology:Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 2Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 3Sexual Function Affected by Stem Cell Transplant According to Long-Term Study 4Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 2Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 3Promising Data from Paratek Pharmaceuticals' MAR Inhibitor Program Presented in 'Late Breaker' Session at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy 4
(Date:8/20/2014)... Aug. 20, 2014 (HealthDay News) -- Pigs, hearts transplanted ... is twice as long as previously achieved, researchers report. ... ways to use animal organs to shorten transplant waiting ... genetically engineered piglets into baboons, abdomens. The genetic engineering ... response are what enabled the hearts to survive for ...
(Date:8/20/2014)... Thompson HealthDay Reporter WEDNESDAY, ... older women avoid a condition that causes a life-threatening irregular ... had a 10 percent lower risk of developing atrial fibrillation, ... the Aug. 20 issue of the Journal of the ... against the heart rhythm disorder even if they were obese, ...
(Date:8/20/2014)... New York, NY (PRWEB) August 20, 2014 ... and architecture firm Perkins Eastman is pleased ... and design services in China and ... internationally recognized Principal Richard Sprow AIA has ... continue his 40-year career in healthcare planning and design ...
(Date:8/20/2014)... A common approach to treating kidney failure by removing ... chances for people who suddenly developed the condition, in ... Pittsburgh School of Medicine. , Their findings, published online ... hemodialysis, an aggressive method that is standardly used for ... definitive benefit to the patient. , "Our findings question ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 ... the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... notes that two U.S. Senators from New York are ... seek a recall of the devices. In a letter ... both Democrats, also implored the agency to seriously consider ...
Breaking Medicine News(10 mins):Health News:Pigs' Hearts Beat for a Year in Baboons' Abdomens 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4
... and candidates faster, brings unprecedented functionality and ease of use to ... ... -- Dayak, the leading online recruiting marketplace used by ... more efficiently, today launched a new version of its user interface ...
... are trying to economize by choosing cheaper shipping methods , ... ... www.medisave.net ), a leading global medical equipment merchant with ... today announced that despite the global credit crunch, global sales have ...
... Indication this Year; Data Demonstrate High,Durable Response Rates ... a Rituximab-Containing Regimen, FRAZER, Pa., Nov. 3 ... U.S. Food and Drug Administration (FDA) has,approved TREANDA(R) ... with indolent B-cell non-Hodgkin,s lymphoma (NHL),that has progressed ...
... of Allergy and Infectious Diseases (NIAID) scientist Theodore E. ... with areas of brain tissue swelling in people infected ... form around dead, calcified cysts that result when larvae ... brain. The illness caused by T. solium ...
... provider team up to market ... final expense planning, ... Corporation International (NYSE: SCI ) have formed a,unique partnership through ... Final Expense insurance., This is an extraordinary combination of services ...
... 2008, JUPITER, Fla., Nov. 3 From November 15 -17, ... promote,National Smoke Out Day, November 20, and to promote her new ... -- MISS AMERICA 2008 KIRSTEN HAGLUND, WILL BE AVAILABLE ... NOVEMBER 15-17 TO PROMOTE SAVING LIVES, AND ...
Cached Medicine News:Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 2Health News:Dayak Makes Hiring Even Easier, Unveils New Version Of Web Interface For Employers 3Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 2Health News:Despite Credit Crunch, Medisave Sees Strong Sales Increase in 2008 3Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 2Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 3Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 4Health News:Video: Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma 5Health News:SLAICO and SCI Form Partnership 2
Replacement bulb for Vibratome light system....
The V-Block adapter is designed to allow round posts to be placed in the Vibratome vice....
This is a perfect tool for retrieving free floating sections from the Vibratome bath....
... Works includes everything from the care ... fuse, Spare Fluorescent Bulb, additional Vibratome ... Blocks, and a Specimen Tray. ... stage, 1/2" speciment mounts, replacement rotating ...
Medicine Products: